Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma

• Status: Recruiting
• Trial end date: 2024-04-01

Summary

Comparison of the efficacy and safety of rituximab combined with fotemustine, pemetrexed, dexamethasone and rituximab in combination with methotrexate, cytarabine and dexamethasone as first-line regimens in the treatment of primary central nervous system lymphoma

• Phase: Phase 4

Details

• Lead Sponsor: Mingzhi Zhang
• Treatments: BB 1101; Cytarabine; Dexamethasone; Dexamethasone acetate; Fotemustine; Methotrexate; Pemetrexed; Rituximab